HilleVax, a Phase 2 biotech developing a novel norovirus vaccine in-licensed from Takeda, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
HilleVax was formed through the collaboration of Frazier and Takeda Pharmaceuticals to develop HIL-214, a virus-like particle based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. An open IND was transferred to HilleVax from Takeda in September 2021, under which the company plans to initiate a Phase 2b trial in infants in the 2Q22, with top-line data expected in the 2H23.
The Boston, MA-based company was founded in 2019 and plans to list on the Nasdaq under the symbol HLVX. HilleVax filed confidentially on October 19, 2021. J.P. Morgan, SVB Leerink, Stifel, and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
